Back to results
US 2019/0240287 A1Published application
Inhibitor of rna polymerase ii
AssigneeLinnane Pharma AB
InventorsCatharina SVANBORG, Nina FILENKO, Ines AMBITE
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeLinnane Pharma AB
InventorsCatharina SVANBORG, Nina FILENKO, Ines AMBITE
Estimating the term…
An inhibitor of RNA polymerase II is described, wherein said inhibitor is selected a moiety which targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. Particular examples of such inhibitors are polypeptides expressed by a gene selected from lldD, lldR, nlpD or rfaH of a bacterial species, such as a commensal bacteria or asymptomatic carrier, or a variant of said protein. Inhibitors may be based upon bacterial Sigma S or NplD proteins. These inhibitors are useful in therapies, to suppress protein expression. Thus they may be used as immunosuppressants, anti-inflammatory or anti-infection agents.
A pharmaceutical composition comprising an inhibitor of RNA polymerase II and a pharmaceutically acceptable carrier, wherein said inhibitor targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C.
(canceled)
A method for preparing an inhibitor of RNA polymerase II that is expressed by a bacterial species which comprises culturing suitable bacteria in a culture medium, and isolating a factor having RNA polymerase II inhibitor activity from the supernatant.
(canceled)
A method for providing immunosuppression, anti-inflammatory or anti-infection therapy to a patient in need therefore, the method comprising administering to the patient an effective amount of an inhibitor of RNA polymerase II.
18-27. (canceled)
Dependencies are inferred from the claim text.